Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLYSYN in AML with Minimal Residual Disease
NCT02789254Phase 2Completed
- Sponsor
- Synimmune
- Start
- Feb 2017
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of FLYSYN in acute myeloid leukemia (AML), sponsored by Synimmune. Started Feb 2017; status: completed.
02
Drugs
FLYSYN
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02789254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789254.